Literature DB >> 29111426

When movement disorders hurt: Addressing pain in hyperkinetic disorders.

Maja Relja1, Vladimir Miletić2.   

Abstract

Pain is an important nonmotor symptom in movement disorders. Dystonia is a hyperkinetic movement disorder characterized by involuntary, sustained or intermittent muscle contractions causing abnormal movements, postures or both. Contrary to common views the nonmotor symptoms are present in dystonia patients. Pain is a prevailing feature of cervical dystonia (CD), the most common form of focal dystonia. The mechanism of pain in CD remains mostly unknown, but there are growing evidence that it could not be only the consequence of muscle hyperactivity. We have shown that botulinum toxin (BoNT) produced pain relief before muscle relaxation and that effect on pain relief lasted longer than the effect on motor improvement. More and more data suggest that pain relief could be attributed to the direct effect of BoNT type A on central nervous system. Pain, depression, and anxiety have been shown to be significant determinants of QoL in focal dystonia patients. Routine clinical examination in patients with dystonia should include evaluation of motor as well as non-motor symptoms. Selective rating assessment should be used in clinical practice to quantify pain. Specific assessment of pain is important to determine the effect of BoNT as the most effective treatment in focal dystonia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Botulinum toxin; Dystonia; Non-motor symptoms; Pain

Mesh:

Year:  2017        PMID: 29111426     DOI: 10.1016/j.parkreldis.2017.08.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors:  Hsiangkuo Yuan; Stephen D Silberstein
Journal:  Handb Exp Pharmacol       Date:  2021

2.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU.

Authors:  Farwa Ali; Eelco F Wijdicks
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.532

Review 4.  Central Effects of Botulinum Neurotoxin-Evidence from Human Studies.

Authors:  David Weise; Christopher M Weise; Markus Naumann
Journal:  Toxins (Basel)       Date:  2019-01-06       Impact factor: 4.546

Review 5.  The role of sensory information in the pathophysiology of focal dystonias.

Authors:  Antonella Conte; Giovanni Defazio; Mark Hallett; Giovanni Fabbrini; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2019-04       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.